Lundbeck
As of the edition of 20 October 2026, Lundbeck runs 34 drugs, 19 of them marketed; it is on route A at 9 targets and on route B at 14 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 10 company names in this family.
- Chelsea Therapeutics: acquired in 2014; successor H. Lundbeck A/S
- Longboard Pharmaceuticals: acquired in 2024; successor H. Lundbeck A/S
Drugs by status
| Status | Count |
|---|---|
| Marketed | 19 |
| Active | 2 |
| Went quiet | 7 |
| Stopped | 5 |
| Withdrawn from market | 1 |
| Total | 34 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Escitalopram | Ended 2026 (exclusivity) | 4 |
| Metronidazole | none listed | 0 |
| Furosemide | none listed | 2 |
| Memantine | none listed | 5 |
| Citalopram | none listed | 3 |
| Allopurinol | none listed | 0 |
| Indomethacin | none listed | 3 |
| Carbamazepine | none listed | 10 |
| Vortioxetine | Ends 2031 (patent) | 5 |
| Brexpiprazole | Ends 2028 (patent) | 2 |
| Nalmefene | none listed | 9 |
| Eptinezumab | Ends 2032 (computed from the first US licence) | 2 |
| Droxidopa | none listed | 3 |
| Vigabatrin | none listed | 3 |
| Clobazam | none listed | 0 |
| Flupentixol | none listed | 2 |
| Melperone | none listed | 0 |
| Zuclopenthixol | none listed | 2 |
| Stanozolol | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 9 targets, route B at 14 targets.
All 23 rows on route A or B
In the product23 company-target rows on route A or B; 20 are not shown here, and no score is.
See all 23 targets where Lundbeck needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 61 trials led
- Nervous system: 46 trials led
- Heart and blood vessels: 6 trials led